



Vivinex Impress[™] enhances the intermediate vision of monofocal patients



Vivinex Impress™ provides greater than 1 line of binocular visual acuity improvement at 66 cm

Interim results of a running multicentre study¹






Vivinex Impress™ provides the same best-corrected mean distance acuity as a standard monofoal aspheric IOL¹

Vivinex Impress[™] improves intermediate visual acuity at 66 cm (-1.5 D defocus) by more than 1 line¹


Vivinex Impress™ improves intermediate vision and provides consistant refractive predictability

Monocular distance-corrected visual acuity at 1 month




- No difference in best-corrected mean distance visual acuity at 4 m between Vivinex Impress[™] and a standard monofocal aspheric IOL¹
- Approximately 1 line improvement in distance-corrected visual acuity at 66 cm in the Vivinex Impress™ group¹

Absolute value deviation from target postop spherical equivalent at 1 month¹



- Refractive predictability was excellent in both Vivinex Impress[™] and the standard monofocal aspheric groups¹
 - within 0.25 D of target: 60 % vs 55 %
 - within 0.50 D of target: 87 % vs 77 %
 - within 0.75 D of target: 100 % vs 91 %

So how does Vivinex Impress™ work?



This image is for illustrative purposes only and is not an exact representation of the product.

The central optical element creates variations in power that provide an extended range of focus and improved intermediate vision.

Vivinex Impress™ looks the same as a standard monofocal IOL.²

Benefits of the Vivinex[™] platform



Glistening-free

Glistening-free hydrophobic acrylic IOL material^{3,4}



Improved Image Quality Incorporates the Vivinex[™] proprietary aspheric optic design which partially compensates for corneal spherical aberration and is more tolerant to sources of coma than standard aspheric designs⁵



Reduction of PCO

Active oxygen processing treatment, a smooth surface and square optic edge to reduce PCO^{3,6,7,8,9,10,11,12}





Smooth IOL unfolding and capsular bag stability

Textured rough haptic surface designed to reduce potential for adhesion to the optic surface during delivery, and provides better grip inside the capsular bag

Delivered in the preloaded multiSert™ injector

Push and screw modes and the ability to control insertion depth $Vivinex^{\mathsf{TM}}$ multiSert is a 4-in-1 delivery system that allows you to achieve outstanding delivery consistency with your choice of injection and insertion style is





Delivery into capsular bag insert shield:
Default position

Delivery through incision wound tunnel insert shield:
Advanced position

Preloaded injectors are:

Easier to prepare, increasing safety by:14,15,16,17,18,19

- Reducing risk of contamination and infection
- Reducing risk of IOL damage

More efficient in the OR:16,18


- Minimising time spent preparing the IOL delivery system
- Creating fewer instruments to reprocess

More predictable:18

 Increasing predictability and consistency of IOL delivery

Specifications

	Vivinex Impress™
Model name	XY1-EM
Optic design	Biconvex with square, thin and textured optic edge Anterior: Aspheric design
Optic & haptic materials	Hydrophobic acrylic Vivinex™ with UV- and blue light filter
Haptic design	Textured-rough haptic surface
Diameter (optic/OAL)	6.00 mm / 13.00 mm
IOL Power (Spherical equivalent)	+6.00 D to +30.00 D in increments of 0.50 D
Nominal A-constant*	118.8
Injector	multiSert [™] preloaded
Front injector tip outer diameter	1.70 mm
Recommended incision size	2.20 mm



Delivered by the **multiSert**[™] preloaded injector



C € 0123 2023-08-15_HS0E_XY1-EM_BR_EN

References: 1. HOYA data on file. CTM-23-P0105, HOYA Medical Singapore, Pte. Ltd, 2023 2. HOYA data on file. RnD-20-367, HOYA Medical Singapore, Pte. Ltd, 2023 3. Tandogan, T. et al. [2021]: In-vitro glistening formation in six different foldable hydrophobic intraocular lenses. In BMC Ophthalmol 21, 126. 4. Auffarth et al. [2023] Randomized multicenter trial to assess posterior capsule opacification and glistenings in two hydrophobic acrylic intraocular lenses. Sci Rep 13, 2822. 5. Pérez-Merino, P.; Marcos S. [2018]: Effect of. In: hintraocular lenses assess posterior capsule opacification with two hydrophobic acrylic intraocular lensess: 3-year results of a randomized the pacification with two hydrophobic acrylic intraocular lenses: 3-year results of a randomized results of a randomized results of a randomized multicenter and perfective surgery 45 [9], p. 1030-1334. 8. Werner, L. et al. [2019]: Evaluation of clarity characteristics in a new hydrophobic acrylic intraocular lenses of prevent posterior capsule opacification. In: Journal of cataract and refractive surgery 45 [9], p. 1035-1040. 10. Farukhi, A. et al. [2019]: Evaluation of uveal and capsule biocompatibility of a single-piece hydrophobic acrylic intraocular lenses with ultraviolet-constraint on the posterior surface. In: Journal of practive surgery 45 [9], p. 1085-1040. 10. Farukhi, A. et al. [2019]: An In Vitro Human Lens Capsular Bag Model Adopting a Graded Culture Regime to Assess Putative Impact of IOLs on PCO Formation. In: Investigative ophthalmology & visual science 60 [1], p. 113-122. 12. Nanavaty, M. et al. [2019]: Edge profile of commercially available square-edged intraocular lenses: Part 2. In: Journal of cataract and refractive surgery 45 [6], p. 847-853. 13. HOYA data on file. DoF-SERT-102-MULT-03052018, HOYA Medical Singapore Pte. Ltd, 2018 14. Galor, A. et al. [2013]. Management strategies to reduce risk of postoperative infections. In Current ophthalmology reports, I [6], 10.1007/s40135-013-0021-5. 15. Bodnar, Z. et al. [2018]. Noice

Information contained is intended for health care professionals. Please refer to the Instructions For Use for a full list of indications and contraindications. Some of the products and/or specific features as well as the procedures featured in this document may not be approved in your country and thus may not be available there. Design and specifications are subject to change without prior notice as a result of ongoing technical development. Please contact our regional representative regarding individual availability in your country. HOYA, Vivinex Impress, Vivinex and multiSert are trademarks of the HOYA Corporation or its affiliates. ©2023 HOYA Medical Singapore Pte. Ltd. | 455A Jalan Ahmad Ibrahim | Singapore 639939.